openPR Logo
Press release

Saliva test instead of blood test

10-12-2007 05:33 PM CET | Health & Medicine

Press release from: Invitek Biotechnology & Biodesign Ltd.

SaliGene® Collection Tube

SaliGene® Collection Tube

New product – SaliGene® Collection Tube
The SaliGene® Collection Tube is the easiest way to collect and preserve large amounts of DNA from saliva. It is easy-to-use and completely non-invasive, making it ideal for reliable self-administered collection. As part of the PSP® Spin Saliva DNA Kit SaliGene® features an all-in-one system for the collection, preservation, transportation and purification of DNA from saliva. Samples do not require special handling or storage because the DNA is stable for weeks at room temperature in the special DNA stabilizer solution. DNA from SaliGene® performs the same as DNA from blood, but there is no painful blood withdrawl. Therefore this system is highly suitable for children and needle-phobic people. Furthermore the risk of infection with blood-bourne viruses like HIV and Hepatitis is eliminated. The isolated DNA is fully functional for demanding downstream applications and can be processed using high-throughput purification robots. SaliGene® is a perfect tool for genotyping (forensic analysis, paternity testing), pharmacogenetics and molecular diagnostics (e.g. mutation screening) .

Invitek Gesellschaft für Biotechnik & Biodesign mbH
Robert-Rössle-Str. 10
D - 13125 Berlin
Sonja Farhangi
phone: +49 30 9489 3796
fax: +49 30 9489 3795

INVITEK BIOTECHNOLOGY & BIODESIGN LTD. is a worldwide acting provider of innovative, high-quality solutions and technical support to the life sciences and diagnostics industry. Since 1992 the company is internationally acclaimed for its outstanding and high performance technology platform and offers a broad spectrum of superior products for nucleic acid purification, molecular diagnostics, drug discovery and biomedical research. Within the modular product concept “I-tek solution”, Invitek combines its technological developments in complete solutions for molecular diagnostics. An example is the successful introduction of an early warning system for colon carcinoma. Invitek has been certified under EN ISO 9001: 2000 and EN ISO 13485 : 2003 and produces under EC Directive 98/79/EEC (IVD-MD).

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Saliva test instead of blood test here

News-ID: 30472 • Views: 5774

More Releases from Invitek Biotechnology & Biodesign Ltd.

Invitek concludes strategic alliance with Chinese partners
In November 2007 a master agreement between Invitek Biotechnology & Biodesign Ltd., Allrun Nano Science & Technology Co., Ltd. and Research Institute of Micro/Nano Science & Technology in Shanghai Jiao Tong University was signed at the 3rd International Nanotechnology Cooperation Symposium in Shanghai, China. Within this agreement the stragetic cooperation for development of new and innovative separation procedures of biomolecules (nucleic acids, proteins) and cells as well as of novel
New dimension in automation of nucleic acid purification and molecular diagnosti …
Invitek Biotechnolgy & Biodesign Ltd. announces the introduction of a new generation of superparamagnetic nanoparticles for nucleic acid isolation (InviMag® nano). In cooperation with the Chinese company Allrun Nano Science & Technology CO., Ltd. Invitek will adapt and extend its product portfolio for manual and fully automated magnetic extraction of nucleic acids during autumn 2007. The high-performance paramagnetic nanobeads with a controlled surface featuring various functionalities are applicable for efficient
Personalised medicine: milestone in the therapy control of humanised antibodies
CENiMED GmbH, BioTeZ Berlin-Buch GmbH and Invitek Gesellschaft für Biotechnik & Biodesign mbH (company for biotechnology and bio-design) announce their cooperation in the development, production and marketing of Recovery-ELISAs for the therapy control of a new group of therapeutics, the so called humanised antibodies. Humanised antibodies offer unforeseen potentialities in cancer therapy, e. g. for the treatment of mamma carcinoma. Previous therapy control methods, however, could not avoid overdoses which

All 4 Releases